Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut